I Peace announces new iPSC lines to reduce immune rejection risk for U.S. population
October 30, 2024 | 01:55
Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells and iPSC-derived cell therapies, announced that the company has successfully generated iPS cell lines that are homozygous for HLA A, C, and DPA1.
Mobile Version